AI-Enhanced Adaptive Virtual Screening Accelerates Ligand Discovery in Huge Compound Libraries

The search for new drug candidates has always been a numbers game, and the numbers have grown staggering. Commercial and open-source chemical catalogs now contain billions of purchasable molecules, a collection so vast that no laboratory could ever test it directly. Virtual screening, the computational triage of these libraries against disease-relevant protein targets, promised to tame the flood, yet in practice it has been limited by a stubborn trade-off: the most accurate physics-based scoring methods are far too slow to apply to billions of structures, while the fastest methods are too crude to prioritize the right molecules. A new approach published in Nature Biotechnology tackles this dilemma head-on by making the screening process itself adaptive, allowing artificial intelligence to learn, in real time, which regions of a massive chemical library deserve the expensive computational attention and which can be safely set aside.

The core idea behind the method is an active learning loop that governs how computational resources are spent across a screening campaign. Rather than scoring every molecule in a library with the same level of rigor, the algorithm samples molecules at random, sends them through a computationally demanding reference pipeline, and trains a surrogate machine learning model on the results. That model then estimates the likelihood that each untested molecule would rank highly under the full reference protocol. Only the compounds the model is most uncertain about, or most confident will rank near the top, are promoted for exhaustive evaluation. Everything else is filtered out cheaply. The loop repeats, with each round refining the model and progressively concentrating the expensive calculations on the small fraction of the library where the true hits are most likely to reside.

What distinguishes the new work is the sophistication of the reference scoring layer and the way the adaptive policy is engineered around it. The reference pipeline pairs structure-based docking with physics-inspired rescoring and, for a select tier of candidates, more rigorous free-energy estimates, so that the labels the surrogate model learns from are far more reliable than simple docking scores alone. The authors describe an ensemble-based selection strategy in which multiple independently trained models must agree before a molecule is discarded, reducing the risk that a single overconfident network silently eliminates a genuine ligand. Early-stopping criteria and calibration checks are built into the workflow, ensuring that the screening continues until the expected yield of new top-ranked molecules falls below a defined threshold, rather than running for an arbitrary number of cycles.

Benchmarking against billion-scale libraries was central to the study. The team screened catalogs of synthetically accessible compounds against multiple protein targets with well-characterized ligands, including kinase and G-protein-coupled receptor systems, and compared the adaptive workflow against conventional exhaustive docking and against simpler one-shot machine learning filters. The results showed that the adaptive approach recovered the overwhelming majority of the true top-ranking hits identified by exhaustive screening while requiring only a small percentage of the full computational cost. In practical terms, campaigns that would have demanded months of processor time on conventional infrastructure were compressed into days, without sacrificing the quality of the enriched hit lists. The savings scaled with library size, which is precisely the regime where modern screening campaigns need help most.

The authors also stress an important conceptual shift that the method embodies: virtual screening treated not as a static ranking problem but as a sequential decision problem. Each docking calculation performed generates information, and a well-designed screening campaign should choose the next calculation to maximize what is learned about the library as a whole. This framing, borrowed from Bayesian optimization and active learning in other scientific domains, explains why the method improves so dramatically over naive random subsampling. Random subsampling wastes effort on molecules that are obviously unpromising; the adaptive policy instead balances exploration of chemically novel regions against exploitation of regions the models already associate with strong predicted binding, maintaining diversity in the candidate pool and guarding against the collapse onto narrow, easily predicted chemical motifs.

Experimental validation was a critical component of the work, elevating the study beyond a purely computational exercise. Compounds prioritized by the adaptive pipeline were synthesized and tested in biochemical and biophysical assays for several targets, and the experimentally confirmed hit rates substantially exceeded what is typically reported for high-throughput screening of comparably sized collections. Several confirmed ligands occupied binding poses consistent with the computational predictions, and structure-guided analoguing of a subset produced measurable potency improvements. The authors report ligandable chemotypes that had not previously been associated with the targets in question, suggesting that the adaptive workflow does more than rediscover known pharmacophores; it surfaces genuinely novel starting points that conventional screens tend to miss.

For medicinal chemistry teams, the implications are considerable. Ultra-large library screening has already demonstrated, in previous landmark studies, that docked catalogs containing hundreds of millions to billions of molecules can yield potent inhibitors with favorable ligand efficiency. But the computational price of those successes has limited their routine use, concentrating the technique in a handful of well-resourced laboratories. By cutting the compute budget by an order of magnitude or more while preserving hit quality, the adaptive method effectively democratizes the practice. Medium-sized academic groups and biotech companies with modest clusters can now contemplate libraries at scales that were previously out of reach, and industrial groups can run many more target campaigns in parallel, widening the front of early-stage discovery.

The method is not without limitations, and the authors are candid about them. The surrogate models inherit biases from the reference pipeline, so systematic errors in docking or rescoring propagate into the learned filter, albeit in diluted form. Libraries dominated by chemical series very different from the training sample can degrade model confidence, requiring longer exploration phases. There are also open questions about how best to adapt the approach when multiple objectives, such as predicted potency, synthetic accessibility, and off-target liability, must be balanced simultaneously. The team suggests that extending the active learning framework to multi-property optimization is a natural next step, as is coupling the workflow with generative models that can propose and evaluate hypothetical compounds beyond the boundaries of any fixed catalog.

Broader significance aside, the study lands at a moment when the pharmaceutical industry is re-evaluating how artificial intelligence should be woven into discovery pipelines. The lesson of this work is a sober and practical one: the value of machine learning in early drug discovery does not come from replacing physics-based evaluation with end-to-end prediction, but from orchestrating where expensive, trustworthy calculations are spent. The adaptive screening framework treats the AI model as an intelligent allocation layer over rigorous science, and the empirical results suggest that this division of labor is the right one. As chemical catalogs continue to expand and as cryo-electron microscopy and AlphaFold-style structure prediction make more protein targets accessible to structure-based design, methods that make billion-scale screening affordable will likely become standard infrastructure. If the reported hit rates and compute savings hold across a wider range of targets, this approach could mark one of those quiet inflection points that reshapes how the field searches for its next generation of medicines.

Subject of Research: AI-enhanced adaptive virtual screening of large compound libraries for ligand discovery

Article Title: AI-enhanced adaptive virtual screening of large libraries for ligand discovery

Article References: Cecchini, D., Nigam, A., Tang, M., Reis, J., Koop, M., Gottinger, A., Nicoll, C. R., Wang, Y., Jayaraj, A., Çınaroglu˘, S. S., Törner, R., Malets, Y., Gehev, M., Padmanabha Das, K. M., Churion, K., Kim, J., Thomas, N., Li, Y., Seo, H.-S., … Gorgulla, C. (2026). AI-enhanced adaptive virtual screening of large libraries for ligand discovery. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03217-x

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03217-x

Keywords: virtual screening, artificial intelligence, drug discovery, active learning, molecular docking, ligand design, machine learning, large chemical libraries, hit identification, structure-based drug design, surrogate models, Nature Biotechnology